315 related articles for article (PubMed ID: 30635578)
1. CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy.
Chen S; Fan J; Zhang M; Qin L; Dominguez D; Long A; Wang G; Ma R; Li H; Zhang Y; Fang D; Sosman J; Zhang B
Nat Commun; 2019 Jan; 10(1):150. PubMed ID: 30635578
[TBL] [Abstract][Full Text] [Related]
2. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
[TBL] [Abstract][Full Text] [Related]
3. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.
Wang L; Fan J; Thompson LF; Zhang Y; Shin T; Curiel TJ; Zhang B
J Clin Invest; 2011 Jun; 121(6):2371-82. PubMed ID: 21537079
[TBL] [Abstract][Full Text] [Related]
4. GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology.
Lin GH; Snell LM; Wortzman ME; Clouthier DL; Watts TH
J Immunol; 2013 May; 190(9):4627-39. PubMed ID: 23536631
[TBL] [Abstract][Full Text] [Related]
5. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
6. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.
Yegutkin GG; Marttila-Ichihara F; Karikoski M; Niemelä J; Laurila JP; Elima K; Jalkanen S; Salmi M
Eur J Immunol; 2011 May; 41(5):1231-41. PubMed ID: 21469131
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.
Teijeira A; Labiano S; Garasa S; Etxeberria I; Santamaría E; Rouzaut A; Enamorado M; Azpilikueta A; Inoges S; Bolaños E; Aznar MA; Sánchez-Paulete AR; Sancho D; Melero I
Cancer Immunol Res; 2018 Jul; 6(7):798-811. PubMed ID: 29678874
[TBL] [Abstract][Full Text] [Related]
8. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
[TBL] [Abstract][Full Text] [Related]
9. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial immunotherapy induces tumor-infiltrating CD8
Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
[TBL] [Abstract][Full Text] [Related]
11. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
12. The volatile anesthetic isoflurane induces ecto-5'-nucleotidase (CD73) to protect against renal ischemia and reperfusion injury.
Kim M; Ham A; Kim JY; Brown KM; D'Agati VD; Lee HT
Kidney Int; 2013 Jul; 84(1):90-103. PubMed ID: 23423261
[TBL] [Abstract][Full Text] [Related]
13. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
[TBL] [Abstract][Full Text] [Related]
14. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
15. Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.
Bartkowiak T; Jaiswal AR; Ager CR; Chin R; Chen CH; Budhani P; Ai M; Reilley MJ; Sebastian MM; Hong DS; Curran MA
Clin Cancer Res; 2018 Mar; 24(5):1138-1151. PubMed ID: 29301830
[No Abstract] [Full Text] [Related]
16. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory Molecules PD-1, CD73 and CD39 Are Expressed by CD8
Smith CJ; Snyder CM
Front Immunol; 2021; 12():704862. PubMed ID: 34335618
[TBL] [Abstract][Full Text] [Related]
18. Blockade of CD73 delays glioblastoma growth by modulating the immune environment.
Azambuja JH; Schuh RS; Michels LR; Iser IC; Beckenkamp LR; Roliano GG; Lenz GS; Scholl JN; Sévigny J; Wink MR; Stefani MA; Battastini AMO; Figueiró F; Teixeira HF; Braganhol E
Cancer Immunol Immunother; 2020 Sep; 69(9):1801-1812. PubMed ID: 32350590
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
